共 50 条
- [21] A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (09):
- [27] Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine Journal of Human Hypertension, 2007, 21 : 374 - 380
- [30] Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (06):